Join our Lonza experts James Berrie and Eddy BERTHIER for an upcoming webinar, where they will explore innovative strategies and good practices to accelerate the pathway into clinical development for novel biotherapeutics. This session will delve into comprehensive and integrated drug substance/drug product DNA-to-IND programs designed to expedite development across various modalities, including monoclonal antibodies, bispecific antibodies, Fabs, Fc-fusions and non-Fc recombinant proteins. Register today: https://lnkd.in/e2F8X259 📅 Monday, 8 July 🕝 11am EDT / 5pm CET #Lonza #Biologics
Lonza’s Post
More Relevant Posts
-
SKIP the rat/mouse race of hybridoma-based Antibody discovery. Human naïve or synthetic libraries for Ab discovery was one of the most eye opening discovery techniques that I’ve learned when I started at WuXi. Let’s learn together! DM if you want to see how it can be used in your research. #antibodies #antibodydiscovery #mabs #biologics #innovation
WuXi Biologics has constructed human naïve libraries from 50+ donors with more than1*10¹¹ transformants representing nearly all of the human antibody V-gene repertoire. WuXi Biologics has also designed and constructed human synthetic libraries based on dominant germline pairs of heavy and light chains with more than 1*10¹² transformants. We can help you discover your next high-quality antibody therapeutic lead candidate. Learn more about WuXiLibAb™: https://lnkd.in/e5CCJuNZ #phagedisplay #antibodydiscovery #antibodyengineering #humanantibody #invivostudies #biopharma #biologics #biotherapeutics
-
-
📢 Revolutionizing Oral Biologic Delivery with VHH Antibodies 🔍 The article discusses the potential of VHH antibodies in transforming the oral delivery of biologics. Traditional IgG antibodies face challenges in oral therapies due to their large size and sensitivity to degradation. In contrast, VHH antibodies, derived from camelids, offer enhanced stability and functionality. They are smaller, more resistant to extreme conditions, and can be absorbed better in the intestinal lining. Clinical trials have shown promising results, potentially revolutionizing oral antibody therapies in the future. #BioprocessUpdates #VHHantibodies #oraldelivery #biologics #IgGantibodies #camelids #stability #functionality #intestinalabsorption #clinicaltrials #revolutionizingtherapy #oralantibody #futureofmedicine #biotechinnovation #nanobodies #medicalbreakthrough ▷ Read the full article here: 📎 https://lnkd.in/djz_VVYF
-
-
Who's up for a bit of summer reading? Take our quiz to test your grasp of antibody variants, antibody domains, and considerations for setting up purification protocols. Then, download our eBook to enhance your knowledge. https://lnkd.in/encrmtWn #mAbs #antibodies #biologics
-
Who's up for a bit of summer reading? Take our quiz to test your grasp of antibody variants, antibody domains, and considerations for setting up purification protocols. Then, download our eBook to enhance your knowledge. https://lnkd.in/dKsum8dt #mAbs #antibodies #biologics
GROW WHAT YOU KNOW: Download the eBook and take the quiz!
cytiva.link
-
Who's up for a bit of summer reading? Take our quiz to test your grasp of antibody variants, antibody domains, and considerations for setting up purification protocols. Then, download our eBook to enhance your knowledge. https://lnkd.in/e48znXik #mAbs #antibodies #biologics
GROW WHAT YOU KNOW: Download the eBook and take the quiz!
cytiva.link
-
Who's up for a bit of summer reading? Take our quiz to test your grasp of antibody variants, antibody domains, and considerations for setting up purification protocols. Then, download our eBook to enhance your knowledge. https://lnkd.in/eprJAEqf #mAbs #antibodies #biologics
GROW WHAT YOU KNOW: Download the eBook and take the quiz!
cytiva.link
-
We have just signed a collaboration agreement with Acumen Pharmaceuticals, Inc. to manufacture their novel therapeutic for the treatment of Alzheimer’s disease. The agreement covers the manufacture of sabirnetug (ACU193), an antibody targeting toxic soluble amyloid beta oligomers (AβOs), for clinical development and commercialization, if approved. Sabirnetug is the first humanized monoclonal antibody to demonstrate selective target engagement of AβOs in a Phase 1 first-in-human study. As AβOs are an early trigger and persistent driver of Alzheimer’s-associated synaptic dysfunction and neurodegeneration, sabirnetug addresses an underlying cause of Alzheimer’s by preventing toxic AβOs from binding to dendritic spines and by preserving neuronal function. Read more about the agreement here: https://lnkd.in/dFF6CtCX #AHealthierWorld #PharmaceuticalManufacturing #Biologics
-
-
Who's up for a bit of summer reading? Take our quiz to test your grasp of antibody variants, antibody domains, and considerations for setting up purification protocols. Then, download our eBook to enhance your knowledge. https://lnkd.in/eVjkWfu7 #mAbs #antibodies #biologics
GROW WHAT YOU KNOW: Download the eBook and take the quiz!
cytiva.link
-
Who's up for a bit of summer reading? Take our quiz to test your grasp of antibody variants, antibody domains, and considerations for setting up purification protocols. Then, download our eBook to enhance your knowledge. https://lnkd.in/dhhSu84h #mAbs #antibodies #biologics
GROW WHAT YOU KNOW: Download the eBook and take the quiz!
cytiva.link
-
Who's up for a bit of summer reading? Take our quiz to test your grasp of antibody variants, antibody domains, and considerations for setting up purification protocols. Then, download our eBook to enhance your knowledge. https://lnkd.in/ddzXnyaN #mAbs #antibodies #biologics
GROW WHAT YOU KNOW: Download the eBook and take the quiz!
cytiva.link
Managing Director: Impact Shine Communications. Experienced Public Relations, Marketing Communications, Government Relations & IR Expert. Consultant Director: Influence Associates/Emobility. WBF: Advisory Board Member.
4wGreat initiative